A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 23, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Breast Cancer

Interventions

DRUG

Sacituzumab Govitecan

Given by IV (vein)

DRUG

Pembrolizumab

Given by IV (vein)

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston